NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. (“Disc” or the “Company”) (NASDAQ: IRON).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Disc and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On January 15, 202 ...

Disc Medicine, Inc. (IRON) closed the last trading session at $82.14, gaining 6.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $122.08 indicates a 48.6% upside potential.The average comprises 12 short-term price targets ranging from a low of $109.00 to a high of $154.00, with a standard deviation of $15.41. While the lowest estimate indicates an increase of 32.7% from the curre ...

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. (“Disc” or the “Company”) (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Disc and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On January 15, 2026 ...

The U.S. Food and Drug Administration (FDA) reviewers on Thursday postponed their decision on an experimental treatment from Disc Medicine Inc. (NASDAQ:IRON) by about two weeks to Feb.10. • Disc Medicine stock is gaining positive traction. What’s pushing IRON stock higher?The drug, bitopertin, is being developed for erythropoietic protoporphyria, a rare blood disorder that causes extreme sensitivity to sunlight.Regulators questioned whether "pain-free time in the sun," a secondary endpoint in trials, was a ...

Core Viewpoint - Disc Medicine, Inc. (NASDAQ:IRON) is positioned positively in the healthcare sector, with an "Outperform" rating from Wedbush, indicating confidence in its potential to outperform market averages [1][6]. Group 1: Company Performance - The current stock price of IRON is approximately $72.46, reflecting a decrease of about 6% or $4.62 from previous levels [3][6]. - The stock has shown volatility, with a daily trading range between $71 and $77.07, and over the past year, it has fluctuated significantly, reaching a high of $99.50 and a low of $30.82 [3][6]. - Disc Medicine's market capitalization is around $2.74 billion, indicating its size and market value within the healthcare sector [4]. Group 2: Investor Engagement - The company recently presented at the 44th Annual J.P. Morgan Healthcare Conference, a significant event for healthcare firms to showcase their advancements and engage with investors [2][5]. - The trading volume of 679,355 shares on the NASDAQ suggests active investor interest, reflecting the market's response to recent developments [4][5].

Company Overview - Disc Medicine has been publicly listed for approximately three years and has experienced a productive journey during this period [3] - The company is on the verge of approval for its lead program and has a robust pipeline of additional programs progressing well [3] Clinical Programs - The presentation will cover three investigational agents: bitopertin, DISC-0974, and DISC-3405, which are not yet approved as therapies anywhere in the world [4] - The company aims to provide updates on the progress towards approval for its lead program and discuss launch strategies [5]

Summary of Disc Medicine Conference Call Company Overview - **Company**: Disc Medicine - **Focus**: Red blood cell biology, specifically manipulating heme and iron metabolism to address various diseases, including rare and common anemias [3][4] Core Programs - **Lead Program**: Bitopertin for Erythropoietic Protoporphyria (EPP) - **Patient Population**: Estimated 14,000 patients in the U.S. with EPP [6] - **NDA Status**: Submitted and under accelerated review, with anticipated approval by late January or early February [7][14] - **Clinical Data**: - Reduction of protoporphyrin IX (PP-9) by 50%-60% in trials [10] - 75% reduction in phototoxic reactions in the Aurora study [12] - High patient satisfaction with reported improvements in disease state [13] - **Pipeline Programs**: - **DISC-0974**: Targets hemojuvelin, in late-stage Phase 2 development for myelofibrosis anemia [7][26] - **DISC-3405**: Targets TMPRSS6, designed to restrict iron for conditions like polycythemia vera and sickle cell disease [8][38] Market Opportunities - **EPP Market**: Potential market size of over $2 billion if all diagnosed patients are treated [46] - **Myelofibrosis Anemia**: Estimated 25,000 patients in the U.S., with a potential market exceeding $4 billion [29][47] - **Polycythemia Vera**: Approximately 75,000 patients, with significant unmet needs and potential for iron restriction therapy [39][40] Launch Strategy - **Sales Team**: 24 representatives ready for launch, focusing on top 120 accounts [19][22] - **Patient Engagement**: Strategies to identify and engage the 8,000 patients who are currently undiagnosed or untreated [48][49] - **Payer Mix**: Favorable payer landscape with 16% commercial, 25% Medicare, and 15% Medicaid [25] Regulatory and Clinical Milestones - **Upcoming Milestones**: - Anticipated FDA action date for bitopertin in late January or early February [46] - Top-line data from the confirmatory Apollo trial expected by late this year or early next year [15][43] - Plans to initiate pivotal trials for myelofibrosis and polycythemia vera in 2027 [42][44] Financial Position - **Capital**: Approximately $791 million available, providing runway into 2029 without assuming revenue from bitopertin [44][45] Conclusion - Disc Medicine is positioned for a significant year with the potential approval of bitopertin and a robust pipeline addressing critical unmet needs in hematology-oncology, with a strong financial foundation to support its growth strategy [46][47]

J.P. Morgan 44th Annual Healthcare Conference Corporate Overview January 2026 Disclaimer and FLS This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Disc's expectations with respect to its preclinical studies, clinical trials and research and development programs, in particular with respect to bitopertin, DISC-0974 and DISC-3405, and any developments or resul ...

WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Lisa Amaya Price, MBA as the company’s Chief Human Resources (HR) Officer. Ms. Amaya Price brings more than 25 years of experience in human resources and organizational leadership, including at multiple comme ...

Financial Position - As of December 31, 2025, the preliminary unaudited cash, cash equivalents, and marketable securities of Disc Medicine, Inc. were approximately $791 million[6] - The estimate of cash and marketable securities is preliminary and subject to change upon completion of the year-end financial close process[7] - The independent registered public accounting firm has not audited or reviewed the preliminary results, indicating no assurance on the figures provided[7] - The company has no intention or obligation to update the preliminary estimate of its cash and marketable securities[7] - Additional information will be required for a complete understanding of the company's financial position and results of operations as of December 31, 2025[7] Business Objectives and Events - The company announced its recent achievements and key business objectives for 2026 on January 12, 2026[9] - Disc Medicine, Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference starting January 12, 2026, with a presentation scheduled for January 14, 2026[10] - The press release detailing the financial results and business objectives is attached as Exhibit 99.1[9] - The presentation materials for the conference are attached as Exhibit 99.2[10] Company Classification - The company is classified as an emerging growth company under the Securities Act[5]